<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03143569</url>
  </required_header>
  <id_info>
    <org_study_id>201701126</org_study_id>
    <nct_id>NCT03143569</nct_id>
  </id_info>
  <brief_title>Ventricular Assist Device Anti-Factor Xa (VAD ANTIX) Monitoring Study: a Prospective Randomized Feasibility Trial</brief_title>
  <acronym>VAD-ANTIX</acronym>
  <official_title>Ventricular Assist Device Anti-Factor Xa (VAD ANTIX) Monitoring Study: a Prospective Randomized Feasibility Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates two different methods for monitoring a patient's anti-clotting [heparin]
      therapy after they receive a heart pump implant [left ventricular assist device -LVAD]. One
      method tests for how long it takes the patient's blood to clot and uses that to determine if
      they are on the right dose of heparin. The other method uses a more direct measure of how
      much heparin is in the blood. The hypothesis is that the method that more directly measures
      how much heparin is in the patient's blood will provide better medical results for the
      patient's care after they have the heart pump implant. To that end, the investigators are
      conducting this feasibility trial to establish the logistics associated with the
      implementation of these heparin monitoring approaches.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart failure is a medical condition that is on the rise in the US and is associated with an
      enormous cost of $30 billion in healthcare expenses. People with heart failure may be treated
      with an LVAD that is connected to their heart and helps it pump the blood from the left side
      of the heart into the blood vessels that delivers blood to the body. These devices can be
      used to treat heart failure for the long term or they can be used while a patient waits for a
      heart transplant. In either case, the use of these devices is increasing.

      One of the primary risks associated with LVADs are those related to blood clotting.
      Maintenance of the LVAD depends on preventing blood clots especially right after the surgery
      that puts them in place. This requires putting patients with LVADs on blood thinners and then
      monitoring the blood thinner levels carefully so that they don't have problems with bleeding
      too easily or, on the other hand, forming blood clots if they aren't on the right dose of
      blood thinners. Excessive bleeding - called hemorrhaging - is the more common problem after
      surgery and half of all patients that receive an LVAD will require a blood transfusion within
      the first 30 days after they receive the device. A laboratory test that measures how quickly
      blood clots is used to determine if the patient has the right amount of blood thinners. The
      current standard test is called &quot;activated partial thromboplastin time [aPTT].&quot; There are
      problems with the reliability of this test because it reacts with other elements in the
      blood. Alternately, there is a test that more directly measures the amount of heparin blood
      thinner rather than coagulation time and may be more reliable than aPTT called anti-factor Xa
      [anti-Xa].

      The investigators have developed process diagrams that show steps for making decisions
      [called nomograms] that tell a nurse or doctor how to manage the heparin levels using test
      results from the aPTT test or the anti-Xa test; however, both tests will be performed at each
      decision time point, but the care team will only be told the results from the testing to
      which their patient is assigned.

      The purpose of this feasibility study is to establish feasibility of using the two nomograms
      to determine which provides the optimal clinical information for improving patients' outcomes
      that have had LVADs placed.

      Potential subjects will be recruited prior to their surgery and may decline to participate
      anytime before or after the surgery takes place. Subjects will be randomized to the aPTT
      nomogram or the anti-Xa nomogram. If they withdraw consent, they will receive the aPTT
      standard of care monitoring. The study procedures are performed by the clinical care team.
      Clinicians will be trained to use the nomograms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 20, 2017</start_date>
  <completion_date type="Actual">July 12, 2018</completion_date>
  <primary_completion_date type="Actual">July 12, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nomogram Feasibility</measure>
    <time_frame>14 days of heparin therapy</time_frame>
    <description>Questionnaires evaluating pragmatic application of nomograms. Question 1: The current heparin nomogram using (aPTT or anti-Xa depending on group) monitoring is easy to follow.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nomogram Feasibility</measure>
    <time_frame>14 days of heparin therapy</time_frame>
    <description>Questionnaires evaluating pragmatic application of nomograms. Question 2: Overall, I am satisfied with the utilization and implementation of the heparin monitoring nomogram.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nomogram Feasibility</measure>
    <time_frame>14 days of heparin therapy</time_frame>
    <description>Questionnaires evaluating pragmatic application of nomograms. Question 3: Overall, I feel that this dosing nomogram is feasible.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nomogram Feasibility</measure>
    <time_frame>14 days of heparin therapy</time_frame>
    <description>Questionnaires evaluating pragmatic application of nomograms. Question 4: When my patient is on the heparin nomogram, I follow the dosing and monitoring instructions exactly.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nomogram Feasibility</measure>
    <time_frame>14 days of heparin therapy</time_frame>
    <description>Questionnaires evaluating pragmatic application of nomograms. Question 5: I often had to seek clarification from a coworker, pharmacist, NP, or MD regarding the nomogram instructions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Success of Nomogram</measure>
    <time_frame>14 days of heparin therapy</time_frame>
    <description>Amount of time sustained in therapeutic anticoagulation range</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nomogram Concordance</measure>
    <time_frame>14 days of heparin therapy</time_frame>
    <description>Compare heparin dosing success between aPTT and anti-factor Xa nomograms. If aPTT was within therapeutic range of nomogram AND anti-factor Xa was within range in therapeutic nomogram, then paired values were deemed &quot;concordent&quot;. Similiarly if both aPTT AND anti-factor Xa were above therapeutic range OR both below therapeutic range, then paired valued were deemed &quot;concordent&quot;. Otherwise values deemd &quot;discordant&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosing Changes</measure>
    <time_frame>14 days of heparin therapy</time_frame>
    <description>Number of dosing changes during heparin therapy until first therapeutic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Therapeutic Dose</measure>
    <time_frame>14 days of heparin therapy</time_frame>
    <description>Amount of time needed to achieve therapeutic dose from heparin initiation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Left Sided Heart Failure</condition>
  <condition>Left Ventricular Assist Device</condition>
  <condition>Anticoagulant Therapy</condition>
  <condition>Gastro Intestinal Bleeding</condition>
  <condition>Thrombosis, LVAD</condition>
  <condition>Anti-factor Xa</condition>
  <condition>aPTT</condition>
  <condition>Heparin</condition>
  <arm_group>
    <arm_group_label>aPTT nomogram</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>aPTT guided heparin management</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-factor Xa nomogram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti-factor Xa guided heparin management</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>aPTT guided heparin management</intervention_name>
    <description>post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.</description>
    <arm_group_label>Anti-factor Xa nomogram</arm_group_label>
    <arm_group_label>aPTT nomogram</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Anti-factor Xa guided heparin management</intervention_name>
    <description>post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device</description>
    <arm_group_label>Anti-factor Xa nomogram</arm_group_label>
    <arm_group_label>aPTT nomogram</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years of age and older

          2. Implantation with HeartMate II® or HeartWare®, LVAD at Barnes Jewish Hospital

        Exclusion Criteria:

          1. Unable to receive heparin-based therapy

          2. Hypercoagulable disorders [factor V Leiden, Antithrombin deficiency, Protein C
             deficiency, Antiphospholipid antibodies or other thrombophilia]

          3. Incarceration

          4. Pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas J Graetz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Anesthesiology, Washington University STL SOM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University in St Louis School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>April 20, 2017</study_first_submitted>
  <study_first_submitted_qc>May 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2017</study_first_posted>
  <results_first_submitted>September 11, 2019</results_first_submitted>
  <results_first_submitted_qc>February 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 25, 2020</results_first_posted>
  <last_update_submitted>February 17, 2020</last_update_submitted>
  <last_update_submitted_qc>February 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Thomas Graetz</investigator_full_name>
    <investigator_title>Assoc Prof of Anesthesiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 31, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT03143569/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>aPTT Nomogram</title>
          <description>aPTT guided heparin management
aPTT guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.
Anti-factor Xa guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device</description>
        </group>
        <group group_id="P2">
          <title>Anti-factor Xa Nomogram</title>
          <description>Anti-factor Xa guided heparin management
aPTT guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.
Anti-factor Xa guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>10 patients, that met all inclusion and exclusion criteria, were enrolled in each arm</population>
      <group_list>
        <group group_id="B1">
          <title>aPTT Nomogram</title>
          <description>aPTT guided heparin management
aPTT guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.
Anti-factor Xa guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device</description>
        </group>
        <group group_id="B2">
          <title>Anti-factor Xa Nomogram</title>
          <description>Anti-factor Xa guided heparin management
aPTT guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.
Anti-factor Xa guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.3" spread="12.3"/>
                    <measurement group_id="B2" value="50.5" spread="13.4"/>
                    <measurement group_id="B3" value="51.9" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>INTERMACS Profile score less than 4</title>
          <description>INTERMACS(R) (Interagency Registry of Mechanically Assisted Circulatory Support) patient profile at the time of implant is a general description of patients receiving LVADs. INTERMACS(R) profile 1 is in Critical cardiogenic shock. INTERMACS(R) profile 2 is in Progressive decline. INTERMACS(R) profile 3 is Stable but inotrope dependent. INTERMACS(R) profile 4 is Resting symptoms. INTERMACS(R) profile 5 is Exertion intolerant. INTERMACS(R) profile 6 is Exertion limited. INTERMACS(R) profile 7 is Advanced NYHA Class 3. The lower the INTERMACS(R) profile, the more severe their heart failure.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Nomogram Feasibility</title>
        <description>Questionnaires evaluating pragmatic application of nomograms. Question 1: The current heparin nomogram using (aPTT or anti-Xa depending on group) monitoring is easy to follow.</description>
        <time_frame>14 days of heparin therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>aPTT Nomogram</title>
            <description>aPTT guided heparin management
aPTT guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.</description>
          </group>
          <group group_id="O2">
            <title>Anti-factor Xa Nomogram</title>
            <description>Anti-factor Xa guided heparin management
Anti-factor Xa guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device</description>
          </group>
        </group_list>
        <measure>
          <title>Nomogram Feasibility</title>
          <description>Questionnaires evaluating pragmatic application of nomograms. Question 1: The current heparin nomogram using (aPTT or anti-Xa depending on group) monitoring is easy to follow.</description>
          <units>Surveys</units>
          <param>Number</param>
          <units_analyzed>Surveys</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Surveys</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Surveys Completed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Affirmative Responses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.45</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Nomogram Feasibility</title>
        <description>Questionnaires evaluating pragmatic application of nomograms. Question 2: Overall, I am satisfied with the utilization and implementation of the heparin monitoring nomogram.</description>
        <time_frame>14 days of heparin therapy</time_frame>
        <population>Collected Survey responses from bedside nurses. All surveys were collected as intended.</population>
        <group_list>
          <group group_id="O1">
            <title>aPTT Nomogram</title>
            <description>aPTT guided heparin management
aPTT guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.</description>
          </group>
          <group group_id="O2">
            <title>Anti-factor Xa Nomogram</title>
            <description>Anti-factor Xa guided heparin management
Anti-factor Xa guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device</description>
          </group>
        </group_list>
        <measure>
          <title>Nomogram Feasibility</title>
          <description>Questionnaires evaluating pragmatic application of nomograms. Question 2: Overall, I am satisfied with the utilization and implementation of the heparin monitoring nomogram.</description>
          <population>Collected Survey responses from bedside nurses. All surveys were collected as intended.</population>
          <units>Surveys</units>
          <param>Number</param>
          <units_analyzed>Surveys</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Surveys</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Surveys Completed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Affirmative Responses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Nomogram Feasibility</title>
        <description>Questionnaires evaluating pragmatic application of nomograms. Question 3: Overall, I feel that this dosing nomogram is feasible.</description>
        <time_frame>14 days of heparin therapy</time_frame>
        <population>Collected Survey responses from bedside nurses. All surveys were collected as intended.</population>
        <group_list>
          <group group_id="O1">
            <title>aPTT Nomogram</title>
            <description>aPTT guided heparin management
aPTT guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.</description>
          </group>
          <group group_id="O2">
            <title>Anti-factor Xa Nomogram</title>
            <description>Anti-factor Xa guided heparin management
Anti-factor Xa guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device</description>
          </group>
        </group_list>
        <measure>
          <title>Nomogram Feasibility</title>
          <description>Questionnaires evaluating pragmatic application of nomograms. Question 3: Overall, I feel that this dosing nomogram is feasible.</description>
          <population>Collected Survey responses from bedside nurses. All surveys were collected as intended.</population>
          <units>Surveys</units>
          <param>Number</param>
          <units_analyzed>Surveys</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Surveys</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Surveys Completed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Affirmative Responses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Nomogram Feasibility</title>
        <description>Questionnaires evaluating pragmatic application of nomograms. Question 4: When my patient is on the heparin nomogram, I follow the dosing and monitoring instructions exactly.</description>
        <time_frame>14 days of heparin therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>aPTT Nomogram</title>
            <description>aPTT guided heparin management
aPTT guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.</description>
          </group>
          <group group_id="O2">
            <title>Anti-factor Xa Nomogram</title>
            <description>Anti-factor Xa guided heparin management
Anti-factor Xa guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device</description>
          </group>
        </group_list>
        <measure>
          <title>Nomogram Feasibility</title>
          <description>Questionnaires evaluating pragmatic application of nomograms. Question 4: When my patient is on the heparin nomogram, I follow the dosing and monitoring instructions exactly.</description>
          <units>Surveys</units>
          <param>Number</param>
          <units_analyzed>Surveys</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Surveys</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Surveys Completed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Affirmative Responses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Nomogram Feasibility</title>
        <description>Questionnaires evaluating pragmatic application of nomograms. Question 5: I often had to seek clarification from a coworker, pharmacist, NP, or MD regarding the nomogram instructions.</description>
        <time_frame>14 days of heparin therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>aPTT Nomogram</title>
            <description>aPTT guided heparin management
aPTT guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.</description>
          </group>
          <group group_id="O2">
            <title>Anti-factor Xa Nomogram</title>
            <description>Anti-factor Xa guided heparin management
Anti-factor Xa guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device</description>
          </group>
        </group_list>
        <measure>
          <title>Nomogram Feasibility</title>
          <description>Questionnaires evaluating pragmatic application of nomograms. Question 5: I often had to seek clarification from a coworker, pharmacist, NP, or MD regarding the nomogram instructions.</description>
          <units>Surveys</units>
          <param>Number</param>
          <units_analyzed>Surveys</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Surveys</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Surveys Completed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Affirmative Responses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.018</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Success of Nomogram</title>
        <description>Amount of time sustained in therapeutic anticoagulation range</description>
        <time_frame>14 days of heparin therapy</time_frame>
        <population>Each group received heparin anticoagulation and had heparin administration guided by a nomogram based on one of two different laboratory assays, aPTT or anti-Xa.</population>
        <group_list>
          <group group_id="O1">
            <title>aPTT Nomogram</title>
            <description>aPTT guided heparin management
aPTT guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.
Anti-factor Xa guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device</description>
          </group>
          <group group_id="O2">
            <title>Anti-factor Xa Nomogram</title>
            <description>Anti-factor Xa guided heparin management
aPTT guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.
Anti-factor Xa guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device</description>
          </group>
        </group_list>
        <measure>
          <title>Success of Nomogram</title>
          <description>Amount of time sustained in therapeutic anticoagulation range</description>
          <population>Each group received heparin anticoagulation and had heparin administration guided by a nomogram based on one of two different laboratory assays, aPTT or anti-Xa.</population>
          <units>% of time patients test was therapeutic</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.8" lower_limit="33.3" upper_limit="53.3"/>
                    <measurement group_id="O2" value="55.8" lower_limit="50.0" upper_limit="63.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nomogram Concordance</title>
        <description>Compare heparin dosing success between aPTT and anti-factor Xa nomograms. If aPTT was within therapeutic range of nomogram AND anti-factor Xa was within range in therapeutic nomogram, then paired values were deemed &quot;concordent&quot;. Similiarly if both aPTT AND anti-factor Xa were above therapeutic range OR both below therapeutic range, then paired valued were deemed &quot;concordent&quot;. Otherwise values deemd &quot;discordant&quot;</description>
        <time_frame>14 days of heparin therapy</time_frame>
        <population>paired aPTT samples compared with antiXa samples</population>
        <group_list>
          <group group_id="O1">
            <title>aPTT Nomogram</title>
            <description>aPTT guided heparin management
aPTT guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.
Anti-factor Xa guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device</description>
          </group>
          <group group_id="O2">
            <title>Anti-factor Xa Nomogram</title>
            <description>Anti-factor Xa guided heparin management
aPTT guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.
Anti-factor Xa guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device</description>
          </group>
        </group_list>
        <measure>
          <title>Nomogram Concordance</title>
          <description>Compare heparin dosing success between aPTT and anti-factor Xa nomograms. If aPTT was within therapeutic range of nomogram AND anti-factor Xa was within range in therapeutic nomogram, then paired values were deemed &quot;concordent&quot;. Similiarly if both aPTT AND anti-factor Xa were above therapeutic range OR both below therapeutic range, then paired valued were deemed &quot;concordent&quot;. Otherwise values deemd &quot;discordant&quot;</description>
          <population>paired aPTT samples compared with antiXa samples</population>
          <units>tests</units>
          <param>Count of Units</param>
          <units_analyzed>tests</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>tests</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="416"/>
                <count group_id="O2" value="416"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>subtherapeutic</title>
                  <measurement_list>
                    <measurement group_id="O1" value="242"/>
                    <measurement group_id="O2" value="166"/>
                  </measurement_list>
                </category>
                <category>
                  <title>therapeutic</title>
                  <measurement_list>
                    <measurement group_id="O1" value="138"/>
                    <measurement group_id="O2" value="223"/>
                  </measurement_list>
                </category>
                <category>
                  <title>supratherapeutic</title>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dosing Changes</title>
        <description>Number of dosing changes during heparin therapy until first therapeutic</description>
        <time_frame>14 days of heparin therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>aPTT Nomogram</title>
            <description>aPTT guided heparin management
aPTT guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.
Anti-factor Xa guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device</description>
          </group>
          <group group_id="O2">
            <title>Anti-factor Xa Nomogram</title>
            <description>Anti-factor Xa guided heparin management
aPTT guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.
Anti-factor Xa guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device</description>
          </group>
        </group_list>
        <measure>
          <title>Dosing Changes</title>
          <description>Number of dosing changes during heparin therapy until first therapeutic</description>
          <units>dosing changes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="1.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Therapeutic Dose</title>
        <description>Amount of time needed to achieve therapeutic dose from heparin initiation</description>
        <time_frame>14 days of heparin therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>aPTT Nomogram</title>
            <description>aPTT guided heparin management
aPTT guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.
Anti-factor Xa guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device</description>
          </group>
          <group group_id="O2">
            <title>Anti-factor Xa Nomogram</title>
            <description>Anti-factor Xa guided heparin management
aPTT guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.
Anti-factor Xa guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Therapeutic Dose</title>
          <description>Amount of time needed to achieve therapeutic dose from heparin initiation</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.0" lower_limit="12.0" upper_limit="60.0"/>
                    <measurement group_id="O2" value="33.0" lower_limit="6.0" upper_limit="48.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Collected during 14 day study duration.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>aPTT Nomogram</title>
          <description>aPTT guided heparin management
aPTT guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.
Anti-factor Xa guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device</description>
        </group>
        <group group_id="E2">
          <title>Anti-factor Xa Nomogram</title>
          <description>Anti-factor Xa guided heparin management
aPTT guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.
Anti-factor Xa guided heparin management: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis</sub_title>
                <description>Thrombotic events</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Bleeding Complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Thomas J Graetz</name_or_title>
      <organization>WASHINGTON UNIVERSITY</organization>
      <phone>3147474155</phone>
      <email>graetzt@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

